With a $5 billion investment, the 3,000-employee campus leads biomanufacturing innovation while embracing AI, education and ...

Cetera Investment Advisers just upped their Amgen game, acquiring an additional 26,309 shares, now holding a hefty 226,219 ...

Flashpoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision-engineered structural ...

In the latest close session, Amgen (AMGN) was down 1.73% at $301.29. The stock's change was less than the S&P 500's daily gain of 0.02%. Meanwhile, the Dow experienced a drop of 0.14%, and the ...

This was the stock's third consecutive day of losses.

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...